MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
10.99
+0.15
+1.38%
After Hours: 10.29 -0.7 -6.35% 19:29 07/17 EDT
OPEN
10.51
PREV CLOSE
10.84
HIGH
11.28
LOW
10.29
VOLUME
598.91K
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
4.110
MARKET CAP
574.52M
P/E (TTM)
-4.0743
1D
5D
1M
3M
1Y
5Y
1D
4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retina gene therapy program
PUBT · 3h ago
4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD
PUBT · 4h ago
4D MOLECULAR THERAPEUTICS - 4D-150 CONTINUES TO BE WELL TOLERATED WITH NO NEW SAFETY FINDINGS
Reuters · 4h ago
4DMT ANNOUNCES POSITIVE 2-YEAR DATA FROM PRISM PHASE 2B CLINICAL TRIAL IN A BROAD WET AMD POPULATION
Reuters · 4h ago
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Barchart · 9h ago
Press Release: 4DMT Announces New Employment Inducement Grants
Dow Jones · 1d ago
Weekly Report: what happened at FDMT last week (0706-0710)?
Weekly Report · 5d ago
Weekly Report: what happened at FDMT last week (0629-0703)?
Weekly Report · 07/06 09:17
More
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.